
    Original Text: Patients with a known hypersensitivity to niraparib, carboplatin, cabazitaxel or an anti-PD1 or anti-PDL1 inhibitor
    Disease/Condition: Hypersensitivity
    Procedure: none
    Drug: Niraparib, Carboplatin, Cabazitaxel
    Biomarker: none
    Computable Rule: HYPERSENSITIVITY == True

Criterion:
    Patients with a history of prior chemotherapy for advanced prostate cancer (including abiraterone acetate, enzalutamide, docetaxel, cabazitaxel, mitoxantrone, or chlorambucil) within 6 months before randomization

Output:
    Original Text: Patients with a history of prior chemotherapy for advanced prostate cancer (including abiraterone acetate, enzalutamide, docetaxel, cabazitaxel, mitoxantrone, or chlorambucil) within 6 months before randomization
    D